Our Company
About Us
Leadership Team
Board of Directors
Advisory Board
Chemoprotection & ALRN-6924
Overview
Role of P53
Preclinical Research
Scientific Publications
Clinical Development
Investors & Media
Careers
Your browser does not support the video tag.
Unlocking p53 to turn chemotherapy into targeted therapy.
Our Science
Contact Us
What's New at Aileron
Press Releases
Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.
Learn More
ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.
Learn More
Latest News
August 6, 2020
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 3, 2020
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
August 3, 2020
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
More News
